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CLINICAL STUDY OF PROSTATIC CANCER
     Kiyoshi KuDo， Miho NAGATA， Nobuyoshi HAyAsHi，
Hirohiko IMAMuRA， Kazuya lwA｝（oTo， i？Vlitsutaka KiMuRA，
M．asanori ］N／1．xTsuBAR．x， Haruo MiMvRA， Kyosuke IVIA”rg，．iJ・yAMA，
       ．Ji．｝ri．ii SuwA， Naohiro AoyAGi， Sa，toru SHTsm／i／）o．，
             Takehiro CHエNo and Ichiro CHINO
   F7』onz the DePartment of乙「？’01・gy， K7・”・ilzσnilve？‘吻Scho・♂・f A4edicine
   Eighty patients witli prostatic canccr， who ’first visited 1〈yorin University School of 1）v（［edicine
from January l976 through Dccember l986， were ana正yzed． Incidcnce of prostatic canceハvas 3．9％
among male inpatients． Age distribution was between 55 and 88， with an average of 72 years old．
The ’most”common ’symptoms were dysuria followed by pollakisuria， hematuria， lumbago・ and
lower extremity pain． Duration from onset of symptom to examination ranged from 6 to 84
months， with an average of 22 months． Clinical stage was A in 7．5％， B in 10％， C in 11．3％ and
D in 71．3％． Accordin．cr to histologidal grade， x・veil， moderately， and poorly differentiated adeno－
carcinomas were observed in 29．9， 29．9 and 40．2％， respectively：
   According to the General Rules for Clinical and Pathological Studies on Prostatic Cancer，
cli’獅奄モ≠?T classification were Te in 8．7％， Ti in 3．8％， T2 in 47．5％， T3 in 27．590 and T4 in
i2．5％． ln the correlation between stage and grade， the largest number of poorly differentiated
adenocarcinoma cases was in stage D． There was no correlation between stage and T classifica－
tion． Of the 80 patients， 71．25MO were treated with antiandrog¢n therapy， 16．25％ with radiation
therapy chiefly， 7．5％ by surgery chiefiy， and5％ with chemotherapy． Survival rate was calculated
by the 1〈aplan－IMeier method． Overall ．survival rate of the 80 patients wa．s 54．4％o at 5 years．
Survival rate by stage were 1001dO in stag’e A at 4 years， and 100％ in B， 87．5600 in C anc1
40．5％ in D at 5 years． Survival・rate by T classification was 81．8％ in Te at 4 years， 7．2％ in T4
at 3 years， and 100％ in Ti， 87．2fO150 in ［1］2， and BO．4％ in T3 at 5 years． respectively． Tlie 5－year
surviyal rate by grade was 49．8％ in well， 79．9％ in moderately， and 42．3％ in poorly differentiated
adenocarcinoma．
                                                  （Acta Urol． Jpn． 35： 1339－1345， 1989）
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対象および方法 Table 3． Chief comp！aints


































Table 1． lncidence of prostatic cancer


































Tota1 20u1 80 （3．9）
Table 2． Age distribution























Table 4．Duration frorn onset of
symptom to examlnatlon
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”rablc 5． Treatment modalitv
1311
No． of cases O／o
Endocrine therapy （E｝
 Medical （M）
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   WELL MODERATELY PCK）RLY
Fig． 3． Correlation between stage and T
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 臨床病期については，stage A 6．0～15．2％， B













































A 77・ 6’v93％， B 36・ 1 n－72． 7％， C 43・ 4“一64％， D
13．8～47．8％と報告されている7－11，13）．自験例では，
Aは6例中1例が肺炎で死亡したほかは，全例4年ま




































 7）T分類は，To 8．7％． T13，8％， T247．5％，
T327．5％， T412．5％であった．
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